Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT). HSCT remains a cornerstone of therapy, offering curative potential; however, it is associated with considerable risks, including non-relapse mortality (NRM), significant morbidity, and long-term complications that continue to be major concerns. In response to these challenges, the FORUM consortium has made substantial progress in improving outcomes for children with ALL undergoing HSCT. The consortium focuses on reducing

Trial Details

NCT ID
NCT07297914
Phase
PHASE2 / PHASE3
Sponsor
Bambino Gesù Hospital and Research Institute
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Total Body Irradiation 8 Gy
  • Ruxolitinib
  • Blinatumomab
  • Cyclophosphamide
  • Total Body Irradiation 12 Gy
  • Corticosteroids
Locations (sample)
  • Vienna, Austria|48.20849,16.37208
  • Prague, Czechia|50.08804,14.42076
  • Copenhagen, Denmark|55.67594,12.56553
  • Helsinki, Finland|60.16952,24.93545
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Male and female patients with allogenic transplant indication for ALL, as determined by national frontline protocols
  • Age ≥3 months to ≤25 years at the time of HSCT.
  • Patients must be in complete remission (with \<5% blasts and absence of leukemia cells in extramedullary sites) prior to undergoing HSCT.
  • Selected donor must be either a matched donor (matched donor category includes 9/10 identical siblings and 10/10 or 9/10 HLA-matched unrelated dono…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →